Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 647 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination of treatment modalities Clear all
Completed Phase 2 Interventional

GW572016 to Treat Recurrent Malignant Brain Tumors

NCT00107003
View directory record Official record
Conditions
Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS
Interventions
lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

NCT00006027
View directory record Official record
Conditions
Endometrial Cancer
Interventions
cisplatin, paclitaxel, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
28
States / cities
Los Angeles, California • Los Gatos, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Not applicable Interventional

The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction

NCT01736605
View directory record Official record
Conditions
Breast Cancer
Interventions
Massage, Massage combined with meditation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Pilot Study on Energy Therapy or Massage to Reduce Fatigue

NCT02758756
View directory record Official record
Conditions
Fatigue
Interventions
Massage, Reiki
Other
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 6, 2026, 10:06 PM EDT
Terminated Phase 4 Interventional

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

NCT00134667
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium)
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 15, 2007 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

NCT02326584
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Standard dose cytarabine for induction, SGN-CD33A, Daunorubicin, High dose cytarabine for consolidation
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Early Phase 1 Interventional

Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer

NCT00527293
View directory record Official record
Conditions
Breast Cancer
Interventions
adjuvant therapy, 3-dimensional conformal radiation therapy, brachytherapy
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
4
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery

NCT00450736
View directory record Official record
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
celecoxib, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer

NCT00003309
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
14
States / cities
Tampa, Florida • Chicago, Illinois • Urbana, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract

NCT00453336
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Interventions
Porfimer Sodium, Photodynamic Therapy
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Early Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides

NCT03281811
View directory record Official record
Conditions
Refractory Mycosis Fungoides
Interventions
Aminolevulinic Acid Hydrochloride, Photodynamic Therapy, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 6, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

NCT06298734
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer, Advanced Melanoma
Interventions
Exercise Program, Diet Program
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 6, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

NCT00667901
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
riluzole, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

Lung Cancer Exercise Training Study

NCT01068210
View directory record Official record
Conditions
Lung Cancer
Interventions
Aerobic Training, Progressive Stretching, Resistance Training, Aerobic and Resistance Training
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer

NCT00354640
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, simvastatin, pharmacological study, adjuvant therapy
Drug · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

NCT00016159
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, lintuzumab, arsenic trioxide, idarubicin, tretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

NCT00436566
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 6, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

NCT00915694
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
nelfinavir mesylate, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Responses to Information on Treatments for Depression

NCT04639765
View directory record Official record
Conditions
Depressive Symptoms
Interventions
CBT without Personalization, CBT with Personalization, ADM without Personalization, ADM with Personalization, Combined Treatment without Personalization, Combined Treatment with Personalization
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Not applicable Interventional

A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS

NCT00002285
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy

NCT00684905
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, leuprolide acetate, adjuvant therapy, neoadjuvant therapy, quality-of-life assessment, brachytherapy
Drug · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 6, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

NCT00590031
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Cisplatin, Irinotecan, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 6, 2026, 10:06 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 6, 2026, 10:06 PM EDT
Not listed Phase 3 Interventional

Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia

NCT03080077
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, Epi-Off
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
10 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 6, 2026, 10:06 PM EDT